Quote:
Originally Posted by Hugh
You accidently missed a bit from the article about Norway and Sweden...
And you are, (accidently, I am sure) in your linked example about Turkey, conflating queuing times with pharmaceutical Supply Change Management - pharma multi-country SCM isn't just about queuing, it's about potential impact of regulatory changes and the requirements for some components in the Supply Chain to have to get licences to Contract Manufactures (which they didn't need to before).
|
That's only because the EU is awkward and insist on it for Norway.
The Turkey article DOES mention all sorts of other paperwork they have to get ready, but the DELAYS are still not 3 months.
Link.
Quote:
The European Medicines Agency (EMA) takes part in projects to foster links with European Union (EU) enlargement countries, to lay the foundations of future co-operation in the Agency's networks.
The Agency's projects fall within the assistance programmes launched by the European Commission to support pre-accession activities.
Current beneficiaries include:
- Albania;
- Bosnia and Herzegovina;
- Kosovo (under United Nations Security Council Resolution 1244/99);
- the former Yugoslav Republic of Macedonia;
- Montenegro;
- Serbia;
- Turkey.
|
Any reason why the UK couldn't be added to that list, unless the EU are awkward, and they wouldn't be like that, would they?
